Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck organon — Renflexis (infliximab-abda biosimilar) Worldwide sales ($M) ($M)
Organon & Co. Form 10-Q / 10-K (CIK 0001821825)
Latest, FY2025
251,000,000
Period ended Dec 31, 2025
Change on a year earlier
-8.4%
274,000,000 in FY2024
History
7 years
Since FY2019
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Organon — Renflexis (infliximab-abda biosimilar) Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 251,000,000 | -8.4% | Organon & Co. SEC Filing (0001628280-26-011125) ↗ |
| FY2024 | Dec 31, 2024 | 274,000,000 | -1.4% | Organon & Co. SEC Filing (0001821825-25-000006) ↗ |
| FY2023 | Dec 31, 2023 | 278,000,000 | +23.0% | Organon & Co. SEC Filing (0001821825-25-000006) ↗ |
| FY2022 | Dec 31, 2022 | 226,000,000 | +21.5% | Organon & Co. SEC Filing (0001821825-25-000006) ↗ |
| FY2021 | Dec 31, 2021 | 186,000,000 | +37.8% | Organon & Co. SEC Filing (0001821825-23-000003) ↗ |
| FY2020 | Dec 31, 2020 | 135,000,000 | +40.6% | Organon & Co. SEC Filing (0001821825-23-000003) ↗ |
| FY2019 | Dec 31, 2019 | 96,000,000 | – | Organon & Co. SEC Filing (0001821825-22-000002) ↗ |
Breakdown
What makes up organon — renflexis (infliximab-abda biosimilar) worldwide sales ($m)
Cite this data
StockData. (2026). Merck Organon — Renflexis (infliximab-abda biosimilar) Worldwide sales ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn_renflexis_ww
See every metric in the Merck KPI table. Data updated Oct 26, 2026.